Beijing Minhai Biotechnology Co., Ltd. is a wholly-owned subsidiary of Shenzhen Kangtai (stock code 300601). It is a listed company whose main business is the development, production and sales of biological vaccine products. The company was founded in 2004 and is located in the Beijing Daxing Bioengineering and Pharmaceutical Industry Base of Zhongguancun Science and Technology Park. It has a domestic new vaccine research and development center and a modern vaccine production base composed of more than a dozen GMP production workshops. The registered capital is 770 million yuan and the investment scale is nearly 1.9 billion yuan. It covers a total area of 235 acres and has 850 employees.
The company has now three products on the market, covering the whole country, and some products have entered the international market. Among its self-developed products, the "cell-free H. influenzae type b combined vaccine" is a domestic quadruple vaccine. Undertake "863" and other major national and Beijing science and technology projects; and established a good technical cooperation relationship with the World Health Organization (WHO) and other foreign institutions. It is a high-tech enterprise, the first batch of G20 enterprises in Beijing, "Beijing Key Laboratory of Research on New Technology of Combined Vaccines", "Beijing New Joint Vaccine Engineering Technology Research Center", "Beijing Engineering Technology Research Center", "Academician Workstation "And" Postdoctoral Workstation ".
Minhai has the courage to shoulder social responsibilities, practice the cultural essence of "creating better vaccines and serving human health", and establish a domestic and even international vaccine enterprise to provide effective protection for human health.
